News from 2007

PregLem SA Announces CHF36m Series B Funding and New Licencing Agreement with HRA Pharma

PregLem, specialising in female reproductive medicine, announced the closing of a CHF36m Series B financing round. This financing will enable development of a molecule licensed-in from HRA Pharma.

Xention Acquires Clinical Development Compound

Xention Ltd has acquired exclusive rights from Scion Pharmaceuticals, Inc. to develop certain ion channel modulators with potential applications for treating a number of diseases, including a novel mechanism for treatment of overactive bladder.

Argenta Discovery and Dr Reddy's progress pre-clinical anti-inflammatory candidate to treat chronic respiratory disease

Argenta Discovery and Dr Reddy's Laboratories, announce a major milestone in their development programme to treat chronic respiratory disease.

Argenta Discovery Genentech Collaboration Extended by 2 years

Argenta has announced that it has extended its integrated contract drug discovery agreement with Genentech, Inc. for a further two years.

Avantium intends to list on Euronext Amsterdam

Avantium has announced its intention to raise new funds through an IPO and to apply for a listing on Eurolist by Euronext Amsterdam.

Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness

Evotec AG has announced positive top-line results from its second phase II trial of EVT 201.

Argenta Discovery Announces a Significant Collaboration Milestone in the Development of Improved Bronchodilators for COPD

Argenta Discovery Limited announces a major milestone in a joint programme with AstraZeneca aimed at identifying improved bronchodilators to treat COPD.

Clavis Pharma Receives European Orphan Drug Designation

Clavis Pharma has announced that the European Commission has granted orphan drug designation to ELACYT (TM) for the treatment of Acute Myeloid Leukaemia.

Evotec to Acquire Renovis, Seek NASDAQ Listing

Evotec AG and Renovis, Inc. have announced that they have entered into a definitive agreement under which Evotec will acquire Renovis in a stock-for-stock transaction valued at c. US$151.8m

Clavis Pharma ASA Strengthens Senior Management

Clavis Pharma ASA is pleased to annouce the appointment of Mr. Geir Christian Melen as CEO. The current CEO, Mr. Tom Pike has been nominated to the position of Executive Chairman.

Evotec Sells its Chemical Development Business to Aptuit for GPB 31.5m in Cash

Evotec AG has announced that it has sold its Chemical Development Business to Aptuit, Inc. for €46.4m ($63.9m) cash

Heptares - New MRC Spin Out - Drug Discovery Company

Heptares Therapeutics Limited is a new drug discovery company whose aim is to apply structural knowledge of G-protein coupled receptors to the design and development of its own drug molecules.

PregLem SA announces CHF32m Series A funding from leading European VC firms and a license agreement with Ipsen

PregLem SA announces the closing of a CHF32m Series A financing round.

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Evotec announced positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia.

Ardana's Oral Growth Hormone Secretagogue Gains Orphan Drug Status

Ardana Plc announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for ARD-07.

Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation

Momenta Pharmaceuticals, Inc. announced today that the Company has initiated dosing of its Phase I study to evaluate the human safety, tolerability, bioavailability and pharmacokinetics of a subcutaneous formulation of M118.

Clavis Pharma Presents Preliminary Clinical Data on ELACYT™ at AACR

Clavis Pharma has presented the first preliminary data from its clinical Phase I/II study with ELACYT™.

Evotec Announces Encouraging FY 2006 Financial Results

Evotec AG reported financial results for the year ended 31 December 2006.

Oxford BioMedica and Sanofi-aventis Enter Global Licensing Agreement to Develop and Commercialise Trovax® for Cancer

Oxford BioMedica and Sanofi-aventis have entered into an exclusive global licensing agreement to develop and commercialise Trovax®.

Evotec Initiates its First Phase I Clinical Study with EVT 302

Evotec AG announces the initiation of its first Phase I study with EVT 302.

Aegerion Pharmaceuticals, Inc. files for IPO

Aegerion Pharmaceuticals, Inc. has filed with regulators to raise up to $86.25million in an initial public offering.

Oxford BioMedica To Acquire Oxxon Therapeutics

Oxford BioMedica, the leading gene therapy company, has entered into an agreement to acquire Oxxon Therapeutics.

Xention Makes Further Board Appointments

Xention Discovery Ltd announced today the appointment of Dr. Kenneth T Cunningham and Professor Wolfgang Hartwig as Non-Executive Directors of the Company.

Clavis Pharma Announces Expansion of ELACYT™ Clincal Development Program

Clavis Pharma announces that it will expand the clinical program for its lead product, ELACYT™, as a potential treatment in metastatic colorectal cancer.